Extracellular Vesicle Activation of Latent HIV-1 Is Driven by EV-Associated c-Src and Cellular SRC-1 via the PI3K/AKT/mTOR Pathway.
Cell Line, Tumor
E1A-Associated p300 Protein
/ metabolism
ErbB Receptors
/ metabolism
Exosomes
/ metabolism
Extracellular Vesicles
/ metabolism
HIV Core Protein p24
/ metabolism
HIV Infections
HIV-1
/ growth & development
Humans
Jurkat Cells
NF-kappa B
/ metabolism
Phosphatidylinositol 3-Kinases
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Proto-Oncogene Proteins pp60(c-src)
/ metabolism
RNA-Binding Proteins
/ metabolism
STAT3 Transcription Factor
/ metabolism
TOR Serine-Threonine Kinases
/ metabolism
Transcription, Genetic
/ genetics
Transcriptional Activation
/ genetics
U937 Cells
Virus Activation
/ physiology
Virus Latency
/ physiology
HIV-1
PI3/AKT/mTOR pathway
SRC-1
c-Src
extracellular vesicle
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
19 06 2020
19 06 2020
Historique:
received:
23
04
2020
revised:
08
06
2020
accepted:
17
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
17
2
2021
Statut:
epublish
Résumé
HIV-1 is a global health crisis that has infected more than 37 million people. Latent reservoirs throughout the body are a major hurdle when it comes to eradicating the virus. In our previous study, we found that exosomes, a type of extracellular vesicle (EV), from uninfected cells activate the transcription of HIV-1 in latent infected cells, regardless of combination antiretroviral therapy (cART). In this study, we investigated the specific mechanism behind the EV activation of latent HIV-1. We found that phosphorylated c-Src is present in EVs of various cell lines and has the ability to activate downstream proteins such as EGFR, initiating a signal cascade. EGFR is then able to activate the PI3K/AKT/mTOR pathway, resulting in the activation of STAT3 and SRC-1, culminating in the reversal of HIV-1 latency. This was verified by examining levels of HIV-1 TAR, genomic RNA and HIV-1 Gag p24 protein in cell lines and primary cells. We found that EVs containing c-Src rescued HIV-1 despite the presence of inhibitors, validating the importance of EV-associated c-Src in latent HIV-1 activation. Lastly, we discovered an increased recruitment of p300 and NF-κB in the nucleus of EV-treated infected cells. Collectively, our data suggest that EV-associated c-Src is able to activate latent HIV-1 via the PI3K/AKT/mTOR pathway and SRC-1/p300-driven chromatin remodeling. These findings could aid in designing new strategies to prevent the reactivation of latent HIV-1 in patients under cART.
Identifiants
pubmed: 32575590
pii: v12060665
doi: 10.3390/v12060665
pmc: PMC7354524
pii:
doi:
Substances chimiques
HIV Core Protein p24
0
NF-kappa B
0
RNA-Binding Proteins
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
p24 protein, Human Immunodeficiency Virus Type 1
0
E1A-Associated p300 Protein
EC 2.3.1.48
EP300 protein, human
EC 2.3.1.48
MTOR protein, human
EC 2.7.1.1
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins pp60(c-src)
EC 2.7.10.2
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : AI078859
Pays : United States
Organisme : NIH HHS
ID : AI074410
Pays : United States
Organisme : NIH HHS
ID : AI127351-01
Pays : United States
Organisme : NIH HHS
ID : AI043894
Pays : United States
Organisme : NIH HHS
ID : NS099029
Pays : United States
Références
Immunity. 2012 Sep 21;37(3):377-88
pubmed: 22999944
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71
pubmed: 15784165
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
J Virol. 2013 Sep;87(18):10313-23
pubmed: 23678164
J Biol Chem. 2006 Sep 15;281(37):27029-38
pubmed: 16849330
Mol Cell Biol. 2004 Nov;24(21):9390-400
pubmed: 15485908
Int J Mol Sci. 2017 Mar 02;18(3):
pubmed: 28257101
J Infect Dis. 2013 Jul;208(1):50-6
pubmed: 23089590
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6981-5
pubmed: 7542783
Biochem Biophys Res Commun. 2015 Aug 14;464(1):292-8
pubmed: 26116769
Sci Rep. 2018 May 16;8(1):7653
pubmed: 29769566
Oncogene. 2000 Nov 20;19(49):5636-42
pubmed: 11114744
Blood. 2017 Aug 10;130(6):777-788
pubmed: 28596424
Proc Natl Acad Sci U S A. 2008 May 6;105(18):6684-9
pubmed: 18443296
Cancer Res. 2014 Mar 1;74(5):1506-1517
pubmed: 24390736
J Cell Physiol. 1991 Apr;147(1):27-36
pubmed: 2037622
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8783-8
pubmed: 27432972
Nat Rev Microbiol. 2014 Nov;12(11):750-64
pubmed: 25402363
Biol Direct. 2013 Jun 07;8:12
pubmed: 23758897
Annu Rev Cell Dev Biol. 1997;13:513-609
pubmed: 9442882
Mol Cancer Ther. 2014 May;13(5):1021-31
pubmed: 24748656
Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50
pubmed: 18166498
Growth Factors. 2005 Sep;23(3):177-82
pubmed: 16243709
Pathog Dis. 2014 Jul;71(2):109-20
pubmed: 24449527
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Cell. 1995 Feb 10;80(3):379-88
pubmed: 7859280
EMBO J. 2003 Dec 15;22(24):6550-61
pubmed: 14657027
J Virus Erad. 2018 Apr 1;4(2):91-98
pubmed: 29682300
Expert Opin Ther Targets. 2011 Jan;15(1):63-74
pubmed: 21110697
Clin Pharmacol Ther. 2013 Jan;93(1):46-56
pubmed: 23212106
Curr Opin Virol. 2016 Jun;18:50-6
pubmed: 27023283
J Biol Chem. 2013 Jul 5;288(27):20014-33
pubmed: 23661700
Cancer Sci. 2014 Nov;105(11):1384-92
pubmed: 25220623
J Biol Chem. 2002 Mar 8;277(10):8004-11
pubmed: 11773079
Front Genet. 2014 Jun 30;5:181
pubmed: 25071818
AIDS. 2016 Mar 27;30(6):849-58
pubmed: 26807966
PLoS Pathog. 2010 Jun 17;6(6):e1000956
pubmed: 20585556
Am J Physiol Cell Physiol. 2007 Jul;293(1):C119-32
pubmed: 17360811
Curr Pharm Des. 2017;23(28):4133-4144
pubmed: 28641535
Biochim Biophys Acta. 2012 Jul;1820(7):940-8
pubmed: 22503788
J Biol Chem. 1987 Dec 25;262(36):17543-8
pubmed: 3480286
J Immunol. 2007 Aug 1;179(3):1969-78
pubmed: 17641064
DNA Cell Biol. 2017 Apr;36(4):243-248
pubmed: 28177658
J Biol Chem. 1998 Sep 18;273(38):24898-905
pubmed: 9733796
AIDS. 2013 Aug 24;27(13):2003-17
pubmed: 23660576
J Neurovirol. 2007 Jun;13(3):210-24
pubmed: 17613711
J Infect Dis. 2015 Jun 1;211(11):1712-6
pubmed: 25512626
PLoS One. 2018 May 3;13(5):e0196230
pubmed: 29723216
Front Microbiol. 2015 Oct 20;6:1132
pubmed: 26539170
Nucleic Acids Res. 2014 Sep;42(15):9862-79
pubmed: 25104021
Mol Biosyst. 2015 Jul;11(7):1946-54
pubmed: 25924008
Breast Cancer Res. 2000;2(3):203-10
pubmed: 11250711
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13519-24
pubmed: 9811832
Cell Metab. 2014 Mar 4;19(3):373-9
pubmed: 24508508
Curr Top Med Chem. 2010;10(4):458-77
pubmed: 20180757
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9202-7
pubmed: 21576473
Viruses. 2014 Apr 22;6(4):1837-60
pubmed: 24759213
Front Microbiol. 2016 Feb 11;7:139
pubmed: 26904012
PLoS One. 2012;7(8):e43691
pubmed: 22937080
J Biol Chem. 2017 Jul 14;292(28):11682-11701
pubmed: 28536264
J Immunol. 2007 Mar 1;178(5):2862-71
pubmed: 17312130
Ann Med. 2014 Sep;46(6):372-83
pubmed: 24897931
Chem Biol. 2007 Jun;14(6):645-57
pubmed: 17584612
J Hematol Oncol. 2009 Nov 12;2:46
pubmed: 19909541
Cancer Sci. 2017 Mar;108(3):520-527
pubmed: 28035720
J Biol Chem. 2004 Nov 12;279(46):48197-204
pubmed: 15331610
J Neurovirol. 2014 Jun;20(3):199-208
pubmed: 24578033
Recent Results Cancer Res. 2014;201:27-65
pubmed: 24756784
Int J Biol Sci. 2012;8(4):470-85
pubmed: 22419892
J Biol Chem. 2001 Dec 7;276(49):45713-21
pubmed: 11574547
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161
pubmed: 22474613
Viruses. 2015 Sep 17;7(9):5066-83
pubmed: 26393640
Immunity. 2010 Jun 25;32(6):766-77
pubmed: 20541955
Biochem Biophys Res Commun. 1995 Oct 24;215(3):1078-87
pubmed: 7488034
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9412-7
pubmed: 26170311
J Biol Chem. 2001 Apr 27;276(17):13505-8
pubmed: 11279224
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63
pubmed: 17911267
Mol Neurobiol. 2014 Feb;49(1):590-600
pubmed: 23999871
J Biol Chem. 2016 Jan 15;291(3):1251-66
pubmed: 26553869
J Neuroendocrinol. 2009 Mar;21(4):229-37
pubmed: 19207820